13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001831942
Total reported value
$1.7B
$1.7B
39 檔
36.3%
In Q1 2024, Commodore Capital LP's U.S. equity holdings reached a combined market value of $1.7B, distributed across 39 disclosed stock positions.
During Q1 2024, Commodore Capital LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ✓ | Merus N V | Stock-Other | 13.13% | — | -8.16% | |
| 2 | VERA | Vera Therapeutics Inc | Stock-Other | 9.13% | — | -41.93% | |
| 3 | NUVL | Nuvalent Inc-a | Stock-Other | 7.47% | -4.20% | +11.77% | |
| 4 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 6.24% | -2.78% | EXIT | |
| 5 | SYRE | Spyre Therapeutics Inc | Stock-Other | 4.78% | -1.10% | — | |
| 6 | ELVN | Enliven Therapeutics Inc | Stock-Other | 4.67% | +2.47% | +36.92% | |
| 7 | PCVX | Vaxcyte Inc | Stock-Other | 3.93% | — | -21.82% | |
| 8 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 3.67% | — | — | |
| 9 | NVLSEUR | Alpine Immune Sciences Inc | Stock-Other | 3.64% | — | -14.60% | |
| 10 | ARVN | Arvinas Inc | Stock-Other | 3.52% | — | +27.50% | |
| 11 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 3.04% | — | -32.26% | |
| 12 | COGT | Cogent Biosciences Inc | Stock-Other | 2.89% | +0.60% | +15.43% | |
| 13 | PHVS | Pharvaris N.V. | Stock-Other | 2.67% | -0.21% | +115.63% | |
| 14 | CLDX | Celldex Therapeutics Inc | Stock-Other | 2.43% | -1.96% | +23.43% | |
| 15 | NKTX | Nkarta Inc | Stock-Other | 2.29% | — | +15.93% | |
| 16 | VRDN | Viridian Therapeutics Inc | Stock-Other | 2.27% | — | +0.55% | |
| 17 | CELC | Celcuity Inc | Stock-Other | 2.25% | — | -11.33% | |
| 18 | KURA | Kura Oncology Inc | Stock-Other | 2.18% | — | +22.19% | |
| 19 | CCCC | C4 Therapeutics Inc | Stock-Other | 1.86% | — | -10.25% | |
| 20 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 1.84% | — | — | |
| 21 | ABVX | Abivax Sa-adr | Stock-Other | 1.81% | — | — | |
| 22 | ISREUR | Isoray Inc | Stock-Other | 1.68% | — | — | |
| 23 | IMVT | Immunovant Inc | Stock-Other | 1.62% | — | -24.90% | |
| 24 | KYTX | Kyverna Therapeutics Inc | Stock-Other | 1.52% | — | — | |
| 25 | ✓ | Engene Holdings Inc | Stock-Other | 1.42% | — | — | |
| 26 | APGE | Apogee Therapeutics Inc | Stock-Other | 1.29% | — | +16.00% | |
| 27 | CABA | Cabaletta Bio Inc | Stock-Other | 1.25% | — | -42.11% | |
| 28 | AUTL | Autolus Therapeutics PLC | Stock-Other | 0.98% | — | — | |
| 29 | ✓ | Third Harmonic Bio Inc | Stock-Other | 0.79% | — | +76.88% | |
| 30 | NGNE | Neurogene Inc | Stock-Other | 0.68% | — | — | |
| 31 | AVU0 | Adverum Biotechnologies Inc | Stock-Other | 0.62% | — | — | |
| 32 | VTGN | Vistagen Therapeutics Inc | Stock-Other | 0.56% | +0.04% | NEW | |
| 33 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 0.51% | — | — | |
| 34 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 0.49% | -1.26% | EXIT | |
| 35 | ✓ | Helix Acquisition CORP Ii | Stock-Other | 0.35% | — | — | |
| 36 | MGNX | Macrogenics Inc | Stock-Other | 0.29% | — | — | |
| 37 | TORCEUR | Adicet Bio Inc | Stock-Other | 0.22% | — | — | |
| 38 | SABS | Sab Biotherapeutics Inc | Stock-Other | 0.06% | -0.31% | -90.00% | |
| 39 | ✓ | Stock-Other | — | — | — |
According to official SEC Form 13F filings, Commodore Capital LP reported a total U.S. public equity portfolio value of $1.7B across 39 disclosed positions in Q1 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including MERUS N V, VERA, NUVL) accounted for 36.3% of total reported equity market value during Q1 2024.
During Q1 2024, Commodore Capital LP's top holdings by market value included MERUS N V (13.1%)、VERA (9.1%)、NUVL (7.5%). The largest single position, MERUS N V, represented 13.1% of total portfolio value.
In Q1 2024, Commodore Capital LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.